Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

disease.

The Company believes that microplasmin may represent a major advance in this area, as detaching the vitreous from the retina has been associated with greatly reducing the growth of new blood vessels (neovascularization) on the retina, which plays a fundamental role in the loss of vision in many diabetic patients.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment in MIVI II DME. This initial study is an important first step in evaluating microplasmin's effect in the diabetic retinopathy population in general. Microplasmin could represent an important treatment option for this patient population, given numerous studies from various groups showing the clinical benefits of vitreous detachment in diabetic retinopathy."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at '/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... DALLAS , March 26, 2015 ... Ablation Market by Procedure Volume, Technology (RF, Microwave, Cryoablation, ... Lung Cancer, Kidney Cancer, Bone Metastasis) - Global Forecasts ... is expected to reach around $462.0 Million growing at ... 91 market data tables and 57 figures spread through ...
(Date:3/26/2015)... Over-the-counter healthcare costs can be a ... new survey of store brand over-the-counter products aimed ... to diabetes, can offer significant savings for those ... Private Label Manufacturers Association, assembled a market basket ... essential for treatment of pre-diabetes and diabetes. These ...
(Date:3/26/2015)... March 26, 2015 A new survey ... comparative effectiveness research (CER) will yield improvements in ... seeing the impact of CER in the current ... survey of stakeholders shows that they view CER ... on health care and decision-making in the next ...
Breaking Medicine Technology:Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4Consumers can keep over-the-counter medicine affordable by using store brands 2NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making 2NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making 3NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making 4
(Date:3/27/2015)... 2015 The 2015 Deep Market ... professional and in-depth study on the current state ... a focus on the Chinese situation. , The ... including definitions, classifications, applications and industry chain structure. ... the international and Chinese domestic situations including development ...
(Date:3/27/2015)... March 27, 2015 Airy Jeanine is ... the official music video for her debut song “Mama’s ... Combining live-action and abstract styling effects, the thematic video ... on YouTube, Vimeo, and assorted outlets. It will be ... of an expanding full-scale marketing strategy. The video promotion ...
(Date:3/27/2015)... 27, 2015 Smile Brands Inc. ( ... business support services to dental groups in the United ... affiliated Castle Dental office in Hendersonville, TN. ... 37075, this new Castle Dental office provides families with ... latest in comprehensive, quality dental care. Hendersonville marks the ...
(Date:3/27/2015)... “ VXi BlueParott Reveal ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... eliminating 90% of ambient noise. , Today, business is ... are important to any professional, voice calls are just ...
(Date:3/27/2015)... March 27, 2015 The Florida Center ... Brain Cancer Cure (ABC2), awarded $350,000 to support brain ... Florida, The Scripps Research Institute and H. Lee Moffitt ... studies with a clear development path and potential to ... the near future. , The awards fund research ...
Breaking Medicine News(10 mins):Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 2Health News:The Florida Center for Brain Tumor Research and Accelerate Brain Cancer Cure Award $350,000 to Florida-Based Researchers 3
... , , , ... 100 mg showed clear advantages over Crinone* (progesterone gel) for ... (PK) study. Progesterone is necessary to increase endometrial receptivity ... , , ENDOMETRIN(R) rapidly reached ...
... , , CHICAGO, Aug. ... ADLS), today announced positive results from an animal study involving ... to measure Restanza,s therapeutic efficacy in treating inhalation anthrax after ... non-human primate study showed that a 14-day course of Restanza ...
... , FRANKLIN, Mass., Aug. 31 PLC Systems Inc. ... vascular medical device-based technologies, today announced that it will demonstrate its ... European Society of Cardiology, August 29 - September 2, 2009 in ... to attend this event. , , ...
... , OAKLAND, Calif., Aug. 31 Life ... that keep mind, body and emotions rigid. Especially during stressful ... is a challenge. The Breema Bodywork Method helps people find ... regardless of what challenges they may be facing. To help ...
... BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... China, announced,today that Sinovac,s H1N1 vaccine has passed the experts ... vaccine is expected to,obtain the production license within this week. ... 2009, State Food and Drug Administration (SFDA),organized and held an ...
... , DEERFIELD, Ill., Aug. 31 Chicago-based Lundbeck ... Achievement by the Illinois Chapter of the Huntington,s Disease Society of ... (HD) community and making a meaningful contribution to the lives of ... past Friday at the fifth annual Celebration of Hope ...
Cached Medicine News:Health News:Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation 2Health News:Recently Published Study Demonstrates Pharmacokinetic Advantages of ENDOMETRIN(R) Over Crinone(R) for Progesterone Supplementation 3Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 2Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 3Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 4Health News:Advanced Life Sciences' Restanza Demonstrates Efficacy in Treating Anthrax Infection 5Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 2Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 3Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at ESC 2009 4Health News:The Breema Center Presents Its Fall Week-Long Intensive on Giving and Receiving Breema Bodywork 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 2Health News:Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA 3Health News:Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntington's Disease Community 2Health News:Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntington's Disease Community 3
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Simple straight stem design for the low-demand patient....
Dual offset femoral stems, hip stems that provide unique and competitive features....
Medicine Products: